力达霉素抗肝癌作用的实验研究

目的观察力达霉素(LDM)在体外、体内对肝癌的抑制作用。方法用四甲基偶氮唑蓝(MTT)方法测定力达霉素和丝裂霉素C对人肝癌BEL-7402细胞及小鼠肝癌22细胞的增生抑制作用。以小鼠移植性肝癌22模型观察不同剂量力达霉素的治疗效果。结果力达霉素和丝裂霉素对人肝癌BEL-7402细胞的半数抑制浓度(IC50)分别为(0.0030±0.0006)nmol/L和(150±27)nmol/L。力达霉素对小鼠肝癌22细胞的IC50为0.025nmol/L。体内试验:力达霉素静脉给药1次及延迟静脉给药3次对小鼠移植性肝癌22细胞的生长均有显著抑制作用。当通过静脉给予1次力达霉素剂量为0.025、0.05和0.1mg/kg时对肝癌22细胞抑瘤率分别为62%、72%和85%。结论力达霉素在体外对肝癌细胞增生有强烈的抑制作用,动物试验有显著疗效

Antitumor effect of lidamycin on hepatoma

Objective To study the in vitro and in vivo antitumor effect of lidamycin on hepatoma.Methods MTT assay was used to determine the growth inhibition of human hepatoma BEL-7402 cells and mouse hepatoma 22 (H22) cells.The therapeutic effects of lidamycin and mitomycin C were determined by animal model of transplantable hepatoma 22(H22)in mice.Results The IC50 values of lidamycin and mitomycin C for hepatoma BEL-7402 were (0.0030±0.0006) nmol/L and (150±27) nmol/L,respectively.For mouse hepatoma H22 cells the IC50 value of lidamycin was 0.025 nmol/L.Given by single intravenous injection at doses of 0.025 mg/kg,0.05 mg/kg and 0.1 mg/kg,lidamycin markedly suppressed the growth of hepatoma 22 in mice by 62%,72% and 85%,respectively.Conclusion Lidamycin shows extremely potent cytotoxicity to hepatoma cells and remarkable therapeutic efficacy against hepatoma in mice.